Definium Therapeutics (DFTX) Other Accumulated Expenses (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Other Accumulated Expenses data on file, last reported at $604000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 131.42% year-over-year to $604000.0 in Q1 2026; TTM through Mar 2026 was $604000.0, a 131.42% increase from a year earlier, with the FY2025 full-year figure at $510000.0, up 83.45% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $604000.0, up from $510000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for DFTX reached as high as $685000.0 in Q2 2024 and fell as low as $45000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $312764.7 across 5 years, with a median of $291000.0 in 2024.
• Across the five-year window, Other Accumulated Expenses soared 2300.0% in 2022 and plunged 60.53% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $72000.0 in 2022, then surged by 401.39% to $361000.0 in 2023, then dropped by 22.99% to $278000.0 in 2024, then surged by 83.45% to $510000.0 in 2025, then climbed by 18.43% to $604000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $604000.0 in Q1 2026, $510000.0 in Q4 2025, and $498000.0 in Q3 2025.